DenmarkDenmark

ScanBalt Soon Independent

10.07.2004

Copenhagen - The meta network Scan-Balt will as of August 1st stand on its own feet and become an independent, non-profit association based on memberships. The cross-border bioregion encompassing Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Norway, Poland, Sweden, the nor-thern part of Germany and north-western part of Russia has been mainly funded by the Nordic Industrial Fund (see EuroBiotechNews 3/03).
3rd ScanBalt Forum in Turku
The Turku Science Park will host the 3rd ScanBalt Forum - organized in co-operation with the 14th Annual Biocity Symposium - on August 25-26, 2004. The forum aims to continue the development of the ScanBalt Competence Region by establishing new scientific platforms and public-private partnerships. The programme with renowned speakers is built on ongoing projects and project ideas. One of them is the ScanBalt Campus that provides a framework for joint activities in knowledge formation and education, for instance by organizing cour-ses and building knowledge centres in the bioregion. Education is given priority also by encouraging students from bioscience communities in the ScanBalt bioregion to present their work at the poster session.

DenmarkDenmark

19.08.2011

Bagsværd – Net profit at Denmark’s Novo Nordisk A/S ballooned in the first six months of 2011, and the firm has raised guidance for the full year results. Sales rose by 9%, from DKK29.1bn to DKK31.7bn, while reported net profit...

DenmarkDenmark

15.08.2011

Copenhagen – Driven by strong sales, Danish drugmaker Lundbeck A/S reported hefty QII/2011 profits, and says it is now expecting full-year results at the upper end of its guided range. Operating profit rose to DKK1.1bn in the...

DenmarkDenmark

12.08.2011

Copenhagen - All is well in Denmark - for now. Danish Drugmaker Lundbeck reported excellent profits in the second quarter but announced its intention to prepare for deep cuts in research. 175 jobs in Denmark and the US (12.5% of...

DenmarkDenmark

06.06.2011

Kvistgaard – Bavarian Nordic A/S of Denmark has raised DKK698m (EUR94m)through a rights issue to fund development of its prostate cancer vaccine Prostvac. A total of 12.9 million shares were sold at DKK54. The company announced...

DenmarkDenmark

12.04.2011

Kvistgaard – Net loss at Danish biopharmaceutical company Bavarian Nordic A/S increased to DKK390m from DKK266m in the previous year, even though revenue grew to DKK314m, up from DKK75m in 2009. Bavarian Nordic’s lead product is...

DenmarkDenmark

09.04.2011

Copenhagen – Despite recent setbacks, Danish TopoTarget A/S still has hopes for its histone deacetylase (HDAc) blocker belinostat (PXD01). The cytotoxic compound for treating lymphoma and solid tumours has failed to show...

Displaying results 11 to 20 out of 194

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-denmark/browse/1/article/scanbalt-soon-independent.html

Print Magazine

Product of the week

Products

Events

All Events

Current issue

All issues